LakeShore Biopharma (LSB) CEO Wang Xu reports option for 203,464 shares

Rhea-AI Filing Summary

LakeShore Biopharma Co., Ltd. director and Chief Executive Officer Wang Xu reported an initial holding of a stock option in a Form 3. The option gives the right to acquire 203,464 ordinary shares at an exercise price of $1.225 per share and expires on December 13, 2034.

According to the vesting terms, 25% of the underlying shares vest on December 31, 2024, and the remaining 75% vest in three equal annual installments on each anniversary of the December 13, 2024 grant date, contingent on continued service with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wang Xu

Role Chief Executive Officer

Type	Security	Shares	Price	Value
holding	Share Option (Right to Buy)	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 203,464 shares (Direct)

Footnotes (1)

1. F1. The option vests as to 25% of the underlying shares on December 31, 2024, and the remaining 75% vests in three equal annual installments on each anniversary of the grant date (December 13, 2024) thereafter, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Underlying shares: 203,464 shares Exercise price: $1.225 per share Option expiration: December 13, 2034 +2 more

5 metrics

Underlying shares 203,464 shares Ordinary shares underlying reported option

Exercise price $1.225 per share Exercise price of share option

Option expiration December 13, 2034 Expiration date of share option

Initial vesting tranche 25% of underlying shares Vesting on December 31, 2024

Remaining vesting 75% of underlying shares In three equal annual installments after December 13, 2024

Key Terms

Share Option (Right to Buy), underlying shares, vesting, expiration date

4 terms

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)""

underlying shares financial

"The option vests as to 25% of the underlying shares on December 31, 2024"

vesting financial

"The option vests as to 25% of the underlying shares on December 31, 2024"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2034-12-13T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 04/10/2026 - 07:51 AM Learn about SEC filing dates

FAQ

What did LakeShore Biopharma (LSB) disclose about Wang Xu in this Form 3?

LakeShore Biopharma reported that CEO and director Wang Xu holds a stock option covering 203,464 ordinary shares. The option is reported as a direct holding and reflects his initial derivative ownership position with the company in this regulatory filing.

How many LakeShore Biopharma (LSB) shares are covered by Wang Xu’s option?

Wang Xu’s reported stock option covers 203,464 underlying ordinary shares. This amount represents the number of shares he can potentially acquire if the option is fully exercised under its terms and subject to the stated vesting schedule and expiration date.

What is the exercise price of Wang Xu’s LakeShore Biopharma (LSB) option?

The exercise price of Wang Xu’s option is $1.225 per ordinary share. This means he can purchase each underlying share at $1.225 once the option has vested and before expiration, subject to the company’s equity plan terms and his continued service.

When does Wang Xu’s LakeShore Biopharma (LSB) option vest?

The option vests 25% of its underlying shares on December 31, 2024. The remaining 75% then vests in three equal annual installments on each anniversary of the December 13, 2024 grant date, provided Wang Xu continues to serve the company.

When does Wang Xu’s LakeShore Biopharma (LSB) option expire?

The reported stock option held by Wang Xu expires on December 13, 2034. He must exercise vested portions of the option before that expiration date; otherwise, any unexercised rights to purchase underlying ordinary shares will lapse automatically.

Is Wang Xu’s LakeShore Biopharma (LSB) option a direct or indirect holding?

The filing identifies the stock option as a direct holding by Wang Xu. The ownership code is listed as “D” for direct, with no footnote indicating any trust, partnership, or other entity holding the derivative security on his behalf.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wang Xu

(Last) (First) (Middle)

C/O BUILDING NO. 2

38 YONGDA ROAD, DAXING DISTRICT

(Street)

BEIJING

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
LakeShore Biopharma Co., Ltd. [ LSB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(1)	12/13/2034	Ordinary Shares	203,464	$1.225	D

Explanation of Responses:

1. The option vests as to 25% of the underlying shares on December 31, 2024, and the remaining 75% vests in three equal annual installments on each anniversary of the grant date (December 13, 2024) thereafter, subject to the Reporting Person's continued service to the Issuer.

	/s/ Xu Wang	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)